A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Part of paid clinical trials in Daphne, Alabama.
- Sponsor
- Puma Biotechnology, Inc.
- Study ID
- NCT06095505
- Phase
- PHASE2
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Alisertib — DRUGAlisertib enteric-coated tablets
Study Details
PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1/PD-1 immunotherapy agent. Up to one additional systemic anti-cancer therapy for SCLC is allowed, for a total of up to two prior treatment regimens. This study is intended to identify the biomarker-defined subgroup(s) that may benefit most from alisertib treatment and to evaluate the efficacy, safety, and pharmacokinetics of alisertib.
Key Dates
- First listed
- Oct 23, 2023
- Start date
- Feb 8, 2024
- Status verified
- Aug 2026
- Primary completion
- Oct 30, 2027
- Completion
- Apr 30, 2028
Study Design
- Enrollment
- 120 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Alisertib50 mg (Prior to Amendment 2) or 60 mg (Amendment 2) or 70 mg (Amendment 3 or later) of alisertib PO BID on days 1-7 of each 21-day cycle
Primary Outcome Measure
Objective response rate (ORR) within biomarker-defined subgroup [ Time Frame: From date of first dose to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 36 months ]
Central Contacts
- Puma Biotechnology, Inc. Clinical Operations Senior Director(424) 248-6500
Locations (30)
Find similar trials in Daphne, AL
Related Studies
- Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial TumorsRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · La Jolla, California
- Tempus Small Cell Lung Cancer Observational Study (Sculptor)Recruiting · Tempus AI · Aurora, Colorado
- Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More TreatmentPHASE2 · Recruiting · Advenchen Pharmaceuticals, LLC. · Birmingham, Alabama